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the number of repeats in the DNA sequence encoding 
kringle IV type 2 (KIV-2). This results in a spectrum of 
circulating apo(a) protein isoforms from 1 to >40 KIV-2 
repeats (3, 6–9) and a corresponding range of molecular 
masses that has been estimated to range from 300 to 800 kDa. 
There is an inverse relationship between the size of the 
apo(a) isoforms and Lp(a) plasma concentration. Addi-
tionally, sequence variants in LPA play a significant role in 
determining plasma Lp(a) levels (4). Large epidemiologic 
studies show a strong link between increases in Lp(a) plasma 
levels and risk of atherosclerotic cardiovascular disease 
(9–12), and Lp(a) is present in human atheroma (13, 14). 
More recently, genetic studies, including Mendelian ran-
domization approaches, have provided convincing evidence 
that LPA is associated causally with coronary heart disease 
and the development of aortic stenosis (15–19).
Despite all that is known about the LPA gene and the 
structure of circulating Lp(a) (4), there is much uncer-
tainty regarding the site(s) of the assembly and production 
of Lp(a), the stability of the bond between apo(a) and 
apoB in plasma, and the site(s) of Lp(a) clearance and deg-
radation. Specifically, there is ongoing controversy about 
where apo(a) and apoB-100 bind to form Lp(a); which 
class of apoB-100 lipoproteins bind to apo(a) to create 
Lp(a); whether the binding of apo(a) is reversible, allow-
ing apo(a) to bind to more than one apoB-100 lipoprotein 
during its lifespan in the circulation; and whether Lp(a) or 
apo(a) leave the circulation via the LDL receptor pathway 
(20–22) or through other potential pathways (22, 23).
The difficulties inherent in understanding Lp(a) metab-
olism have been previously reviewed by various investigators 
including Dieplinger (24) in 1999 and more recently by 
Hoover-Plow and Huang (25) and Lamon-Fava, Diffender-
fer, and Marcovina (23). Importantly, comparison of avail-
able in vivo metabolic studies is confounded by the different 
approaches to isolating Lp(a), different labeling techniques, 
and different dietary and sampling protocols that have 
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been used. Due to the difficulty in studying Lp(a) metabo-
lism, each original research report described in the present 
review also includes an in-depth examination of the relevant 
literature available to the investigators at the time of their 
study. This review will focus on the past, current, and future 
use of stable isotopes in the study of Lp(a) metabolism, 
highlighting critical metabolic uncertainties that exist.
WHERE IS Lp(a) ASSEMBLED?
It is well established that the apo(a) and apoB compo-
nents of Lp(a) are assembled in the liver. Most studies in 
cultured hepatocytes indicate that binding of apo(a) and 
apoB to form Lp(a) occurs either at the surface of the he-
patocyte or in the media (which represents the extracellu-
lar space in vivo), rather than in the intracellular secretory 
pathway (26, 27), with the number of KIV-2 repeats deter-
mining the proportion of newly synthesized apo(a) that is 
secreted rather than degraded intracellularly, possibly by 
the proteasome (27). On the other hand, there are studies 
in cultured cells supporting intracellular assembly of Lp(a) 
(28, 29).There is also evidence supporting a role for trans-
lational efficiency of apo(a) mRNA in the regulation of 
apo(a) production (30).
From the authors’ perspective, studies in cultured cells 
support a model where the assembly of Lp(a) occurs on 
the surface of the liver or in an extra-hepatic space sepa-
rated from plasma.
In contrast to the cellular data, three early in vivo stable 
isotope studies in humans, by Gaubatz et al. (31), Su et al. 
(32), and Frischmann et al. (33), provided support for the 
intracellular assembly of Lp(a). All of these studies used 
deuterated amino acids, but isolated Lp(a), apo(a), and 
apoB in Lp(a) by different methods. Importantly, they all 
observed similar rates of enrichment of plasma Lp(a)-apo(a) 
and Lp(a)-apoB and determined the fractional clearance 
rates (FCRs) for both moieties of Lp(a) to be about 0.25 
pool/day,  lower  than  that  of  LDL-apoB  (which  ranges 
from 0.3 to 0.5 pool/day). Although these data did not rule 
out assembly of Lp(a) from its components at sites on the 
surface of hepatocytes protected from circulating LDL, 
they argued strongly against the fusion of circulating free 
apo(a) with circulating apoB particles. However, Demant 
et al. (34) observed differences in the rise in enrichment of 
Lp(a)-apo(a) and Lp(a)-apoB and, using a more complex 
compartmental model to analyze their data, reported that 
about one-half of Lp(a) was assembled in the liver and 
one-half in plasma, where free apo(a) combined with cir-
culating IDL and LDL. In vivo studies in genetically ma-
nipulated mice support both intracellular and extracel-
lular assembly of Lp(a). Thus, crossing apo(a) transgenic 
mice with apoB transgenic mice resulted in the appearance 
of mature Lp(a) in the circulation concomitant with the 
disappearance of free apo(a) that was present in apo(a) 
transgenic mice, supporting the intracellular assembly of 
Lp(a) (35). In contrast, infusion of human LDL-apoB into 
mice transgenic for human apo(a) generated Lp(a) from 
circulating free apo(a), albeit under very nonphysiological 
conditions (36).
From the authors’ perspective, at the present time, in 
vivo studies of Lp(a) kinetics in humans support assembly 
of Lp(a) within the liver, at the surface of the liver, or in an 
extra-hepatic space separated from plasma.
WHICH apoB LIPOPROTEIN DOES apo(a) BIND TO 
WHEN IT FORMS Lp(a)?
If Lp(a) is assembled within the liver, at the surface of 
the liver, or just outside the liver in a “protected” space from 
which circulating LDL-apoB is excluded, which apoB-100 
lipoprotein is involved? Because VLDL is the major apoB-
100 lipoprotein secreted from the liver, several groups 
have examined the binding of apo(a) to VLDL or the pres-
ence of Lp(a) among lipoproteins isolated in the d < 1.006 
range. The consensus of these studies is that, in vitro, 
apo(a) can bind to a range of lipoproteins (37) and that, in 
vivo, Lp(a) can be isolated from the d < 1.006 range in 
plasma of hypertriglyceridemic subjects and of individuals 
with normal fasting triglycerides (TGs) after they have in-
gested a high fat meal (37–40). However, Krempler et al. 
(41) found no evidence of a precursor-product relation-
ship between VLDL or LDL and Lp(a) after injection of 
radiolabeled VLDL into normal subjects. In addition, when 
VLDL was infused into apo(a) transgenic mice, the appear-
ance of circulating Lp(a) was significantly delayed compared 
with the infusion of LDL (35). If VLDL is not the lipopro-
tein to which apo(a) initially binds, then the nascent Lp(a) 
must arise from the binding of apo(a) to smaller apoB par-
ticles (IDL and/or LDL) and, if this does not occur in the 
circulation, the liver must be secreting one or both of these 
Lp(a) particle sizes. In fact, direct production of LDL-apoB 
has been observed in numerous human lipoprotein kinetic 
studies utilizing both exogenous and endogenous labeling 
approaches (42, 43, 43a). Those studies did not, however, 
examine Lp(a)-apo(a) and Lp(a)-apoB metabolism at the 
same time. We have unpublished data indicating that Lp(a) 
isolated at the density of VLDL and IDL (d < 1.019) has the 
same  FCR  as  Lp(a)  in  the  density  range  of  LDL/HDL.  
Because the pool size of Lp(a) in the d < 1.019 fraction is 
very small, it cannot have the same FCR of the much larger 
pool of Lp(a) in the LDL/HDL density range and also be 
the precursor of the latter.
From the authors’ perspective, based on available data, 
the majority of Lp(a) must enter the circulation as a parti-
cle with a density greater than 1.019.
IS apo(a) IRREVERSIBLY BOUND TO apoB ON Lp(a)?
The earliest reported kinetic studies by Krempler and 
colleagues (44, 45) used radio-iodinated Lp(a) and found 
that the FCR for Lp(a) in normal subjects was 0.3 pool/day. 
They demonstrated equivalent decay curves for serum, pu-
rified Lp(a), and the fractionated protein components of 
Lp(a), indicative of equal clearance rates of Lp(a)-apo(a) 
and Lp(a)-apoB. However, Knight et al. (46), using radio-
labeled Lp(a) isolated by a different method than used by 
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Krempler, observed dissociation and rapid clearance of the 
Lp(a)-apo(a) originally bound to Lp(a)-apoB, with the 
generation of an LDL-like particle in plasma of normal sub-
jects and individuals with familial hypercholesterolemia 
(FH). Knight’s result must be viewed with caution, as there 
is no evidence for a “significant” pool of free apo(a) in the 
circulation and, if dissolution of the apo(a)-apoB complex 
in Lp(a) was followed by rapid clearance of free apo(a) 
[leaving behind an LDL, as suggested by Knight et al. 
(46)], the FCR of that “Lp(a),” which would essentially be 
an LDL labeled in apoB, would be similar to the FCR of 
radiolabeled LDL in normal subjects that Knight et al. (46) 
studied simultaneously.
As noted above, Demant et al. (34), using stable isotopes, 
found that the FCRs for Lp(a)-apo(a) and Lp(a)-apoB were 
similar, indicating that, independent of the site of formation 
of Lp(a), Lp(a)-apo(a) and Lp(a)-apoB remained linked 
until they left the circulation together and were degraded. 
The results of this study have been replicated recently (33). 
Two additional studies from one group, using stable isotopes, 
found differences in the rates of enrichment of Lp(a)-apo(a) 
and Lp(a)-apoB. In the first, Jenner et al. (47) used a lectin-
based isolation method and found FCRs of 0.22 and 0.46 
pool/day  for Lp(a)-apo(a) and Lp(a)-apoB, respectively. 
In the second study, Diffenderfer et al. (48) used immuno-
precipitation of Lp(a) from plasma and reported FCRs 
of 0.10 and 0.26 pool/day for Lp(a)-apo(a) and Lp(a)-
apoB-100. The results of these two studies are incompatible 
with an irreversible combination event for apo(a) and 
apoB-100 in Lp(a). Indeed, the authors offered a model in 
which apo(a) recycles on and off VLDL [forming a TG-rich 
Lp(a) at least once before leaving plasma] (48). Of note, the 
subjects studied by Jenner et al. (47) had baseline lipid lev-
els similar to subjects in other studies in which FCRs for 
Lp(a)-apo(a) and Lp(a)-apoB-100 were the same (32, 33, 35), 
whereas the four subjects studied by Diffenderfer et al. 
(48) were significantly hypertriglyceridemic at baseline.
From the authors’ perspective, at the present time, con-
flicting kinetic data in the literature do not allow us to draw 
a firm conclusion regarding the stability of the apo(a)-
apoB complex during the entire lifespan of Lp(a). The ab-
sence of a significant pool of free apo(a) in plasma, 
however, argues against recycling of apo(a) within the cir-
culation. Future studies that examine larger cohorts and 
can determine the individual kinetics of each apo(a) iso-
form and the apoB associated with each of those isoforms 
will be necessary to answer this important question. Crucial 
to the solution of this problem is the isolation of Lp(a) that 
is completely free of other apoB-containing lipoproteins.
DOES PRODUCTION OR FRACTIONAL CLEARANCE 
DETERMINE THE LEVELS OF Lp(a) IN BLOOD?
From the earliest studies using radiolabeled tracers, plasma 
levels of Lp(a) have correlated very strongly with the pro-
duction rates (PRs) of Lp(a), with little or no relationship 
between levels and the FCR of Lp(a). The opposite was true 
for correlations focused on LDL metabolism, where the LDL 
apoB-100 FCR and not the PR were closely related to LDL 
levels in blood. The importance of production was con-
firmed when Rader and colleagues published results of two 
studies using radio-iodinated Lp(a), which examined the 
important role of apo(a) isoform size on the rate of appear-
ance of Lp(a) in plasma (49, 50). Importantly, while one 
study demonstrated that the inverse relationship between 
apo(a) isoform size and plasma Lp(a) concentration was 
due to differences in apo(a) production rather than clear-
ance, the second revealed that rates of apo(a) production 
determined differences in plasma levels of Lp(a) in peo-
ple with the same apo(a) isoform size. In recent studies 
using stable isotopes, significant correlations between both 
the FCR and PR of Lp(a) and plasma concentrations 
were reported by Jenner et al. (47), whereas Diffenderfer 
et al. (48) only observed a correlation between the PR 
and plasma Lp(a) levels.
From the authors’ perspective, the results published to 
date indicate that, in individuals not receiving any lipid-
altering medications, both fractional clearance and pro-
duction play roles in the regulation of Lp(a) levels in blood. 
Overall, however, the PR is more closely related to plasma 
concentrations of Lp(a) than is the FCR.
The studies described above highlight three key questions 
about the metabolism of Lp(a) that remain unanswered. 
First, does covalent binding of apo(a) to apoB occur out-
side or within the circulation? Second, is the covalent bond, 
once formed, irreversible during the lifetime of apo(a)? 
Third, how is Lp(a) cleared from the circulation?
Lp(a) KINETIC MODELING
Physiological considerations
We have approached the first two questions by develop-
ing a series of mechanistic models. These models serve as 
guidance to understand how stable isotope labeling ki-
netic studies can be used to address questions of Lp(a) 
assembly and its production and clearance in the circula-
tion. The models assume that all proteins synthesized by 
the liver have a common precursor pool of their amino 
acids and, therefore, the plateau of enrichment reached 
by a rapidly turning over protein, such as VLDL-apoB, dur-
ing infusion of a stable isotope of an amino acid can be 
used as the precursor enrichment for all other liver-derived 
proteins (51–53). What is not always recognized is the 
need to account for additional commonalities when dif-
ferent molecules are being studied together on a unique li-
poprotein particle. In studies of apoB and TG kinetics in 
VLDL (54), our multi-compartmental model required that, 
although the TG:apoB ratio could vary among different 
VLDL subfractions (ranging from a large value in the larg-
est subfraction to smaller values down the delipidation 
cascade), the rate constants (or FCRs) for apoB and TG have 
to be the same for any given VLDL pool. This approach was 
taken even earlier by others who modeled apoB and TG 
together (55) and by us when modeling off- and on-statin 
LDL-apoB kinetics data using three radiotracers (56).
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What distinguishes a combined model for Lp(a)-apoB 
and Lp(a)-apo(a) from other combined models, such as 
for VLDL-apoB and VLDL-TG, is that there is a 1:1 molar 
ratio of apoB to apo(a) on every Lp(a) particle (unlike 
apoB:TG ratios, which vary among VLDL particles). This 
fixed molar ratio means that the number of molecules of 
apoB in an Lp(a) pool must equal that of apo(a). Further-
more, if there is no recycling of apo(a) or of apoB within 
Lp(a), the FCR in any Lp(a) pool must be the same for 
apoB and for apo(a) because the exit of one Lp(a) particle 
means the exit of one and only one molecule each of apoB 
and apo(a). It follows then that, because, in each Lp(a) 
pool, the mass and FCR of apoB and apo(a) are equal, the 
flux in and out of that pool must also be the same for apoB 
and apo(a). If one accepts these premises, analyzing Lp(a) 
tracer kinetics data requires the use of a combined model 
for apoB and apo(a) with identical molar masses, fluxes, 
and FCRs for apoB and apo(a) in each Lp(a) pool. A logi-
cal question then is how enrichment curves for Lp(a)-apoB 
and Lp(a)-apo(a) can be different, as seen in some pub-
lished studies (47, 48, 57), if their kinetic parameters are 
the same in every Lp(a) pool. The answer lies in possible 
differences in the synthetic pathways, i.e., the precursor 
pools of apo(a) and apoB for assembly of Lp(a) can have 
different isotopic enrichment.
Below, we explore the possibilities suggested by earlier 
work for Lp(a) assembly: 1) apo(a) and apoB bind inside the 
liver; 2) apo(a) binds extracellularly to apoB lipoproteins in 
the bloodstream; and 3) there is recycling of Lp(a)-apo(a) or 
Lp(a)-apoB. The resulting four models are explained below 
in the context of a primed constant infusion study of a stable 
isotope of an amino acid. We provide the simplest models for 
each possibility. We understand that more complexity than is 
offered by these four models is possible, i.e., there could be 
combinations of models. Additionally, although we include 
the possibility that apo(a) can exit the liver alone and bind to 
apoB in the circulation, we have not allowed apo(a) and 
apoB to separate in the circulation. As a result of the latter 
assumption, when our models include recycling of either 
apo(a) or apoB, this occurs within the liver, after uptake of an 
intact Lp(a). We based this decision on the lack of data sup-
porting a significant pool of free apo(a) in the circulation. 
We are aware of convincing data that a small fraction of Lp(a) 
has been isolated as free apo(a) from serum (58) and frag-
ments of apo(a) can be found in urine (59), but we have not 
included these in our models.
Model I
In this scenario, Lp(a)-apoB and Lp(a)-apo(a) enrich-
ment curves in plasma are identical and, thus, they have 
the same FCR, as observed by Gaubatz et al. (31), Su et al. 
(32), and Frischmann et al. (33). In this model, Lp(a) par-
ticles are assembled within or at the surface of the liver, as 
newly synthesized apo(a) binds to newly synthesized apoB. 
The precursor is the hepatic amino acid pool for both 
Lp(a)-apoB and Lp(a)-apo(a), which, combined with iden-
tical masses and FCRs, means that the Lp(a)-apoB and 
Lp(a)-apo(a) enrichment curves are identical as are their 
FCRs (Fig. 1).
Model II
Lp(a)-apoB has a lower enrichment curve in plasma 
than Lp(a)-apo(a) and has a smaller slope, as in the study 
by Demant et al. (34). There are two possible inferences in 
this case: In model IIa, we can infer that Lp(a) particles are 
made from newly synthesized apo(a) binding partly to 
newly synthesized apoB (in which case the precursor is the 
hepatic amino acid pool for both) and partly to an apoB-
lipoprotein that is already circulating. The latter Lp(a) par-
ticles, formed in plasma in the model, have apoB at a much 
lower enrichment than apo(a). The higher the relative con-
tribution of circulating apoB-lipoproteins (e.g., LDL-apoB) 
to the assembly of the Lp(a), the lower the Lp(a)-apoB en-
richment curve will be compared with the enrichment 
curve of Lp(a)-apo(a). As demonstrated by Demant et al. 
(29), data from the apo(a) and apoB slopes of the enrich-
ments provide the relative contributions of these proteins to 
circulating Lp(a) that is assembled in the liver and one that 
derives from apo(a) binding to a circulating apoB-lipoprotein. 
Despite the existence of two sources of Lp(a) with different 
enrichments in this model, there is only a single catabolic 
pathway into the liver with full degradation of both Lp(a)-
apo(a) and Lp(a)-apoB, meaning that their FCRs and fluxes 
are equal (Fig. 2).
In model IIb, we infer an alternative basis for an Lp(a)-
apoB enrichment curve that is lower than the Lp(a)-apo(a) 
curve. Following liver uptake of circulating Lp(a) parti-
cles, the Lp(a)-apo(a) is degraded while at least some of 
the Lp(a)-apoB can recycle and bind to newly synthesized 
apo(a). Because the Lp(a) entering the liver from the cir-
culation is a mixture of recently labeled Lp(a) and “older” 
unlabeled Lp(a) that was circulating prior to the start 
of the stable isotope infusion, any Lp(a) generated by 
the binding of newly synthesized labeled apo(a) to a 
mixture of newly synthesized apoB and apoB derived 
from circulating Lp(a) that was taken up by the liver will 
have an average enrichment of apoB lower than that of 
apo(a). This inference means that there is a higher flux 
and a higher FCR for Lp(a)-apo(a) than for Lp(a)-apoB. 
It is not possible to choose between model IIa and model 
Fig. 1. Model I: apo(a) and apoB combine to form Lp(a) either 
within the liver, at the surface of the liver, or just outside the liver in 
a compartment protected from circulating plasma. Lp(a)-apo(a) 
and Lp(a)-apoB have the same enrichments, FCRs, and fluxes.
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IIb (Fig. 3) from the tracer studies alone. However, cell 
culture studies indicate secretion of free apo(a) into the 
circulation is unlikely, making the recycling model (model 
IIb) more likely as the explanation of lower enrichment 
in the Lp(a)-apoB curve compared with the Lp(a)-apo(a) 
curve.
Model III
Lp(a)-apoB has a higher enrichment curve in plasma 
than Lp(a)-apo(a) and has a larger slope, as observed by 
Jenner et al. (47) and Diffenderfer et al. (48). There are 
two possible inferences theoretically, as in models IIa and 
IIb. However, the analog to model IIa, which would have 
newly secreted apoB-lipoproteins binding to apo(a) in the 
circulation, requires a large free apo(a) pool in the circula-
tion (if it was small, it would rapidly achieve the precursor 
liver amino acid enrichment). Because there is no evidence 
for such a pool, only one inference, analogous to model IIb 
is possible. We can infer that, following liver uptake of cir-
culating Lp(a), the apoB is degraded while at least some of 
the apo(a) can recycle and bind to newly synthesized apoB. 
This is the opposite of model IIb; but now, because the 
Lp(a) entering the liver from the circulation is at a much 
lower enrichment than the newly synthesized apo(a), any 
Lp(a) generated by the binding of newly synthesized la-
beled apoB to the mixture of labeled and unlabeled apo(a) 
will have an average enrichment of apo(a) lower than that 
of apoB. This inference means that there is a higher flux 
and a higher FCR for Lp(a)-apoB than Lp(a)-apo(a) (Fig. 4). 
This appears to be the favored interpretation in Diffender-
fer et al. (48). Importantly, a very recent paper by Sharma 
et al. (22) demonstrated degradation of Lp(a)-apoB, but 
recycling of Lp(a)-apo(a), in cultured liver cells.
In summary, in all cases, the steady state masses of Lp(a)-
apoB and Lp(a)-apo(a) are equal [as they must be because 
there is one apo(a) and one apoB on each Lp(a)]. In models 
I and IIa, the fluxes of Lp(a)-apoB and Lp(a)-apo(a) 
are equal, and the FCRs of Lp(a)-apoB and Lp(a)-apo(a) are 
equal. In model IIb, the flux and FCR of Lp(a)-apo(a) are 
larger than those of Lp(a)-apoB. In model III, the flux and 
FCR of Lp(a)-apoB are larger than those of Lp(a)-apo(a).
From the authors’ perspective, the models provided above 
attempt to clarify the types of data that have led previous 
investigators studying Lp(a)-apo(a) and Lp(a)-apoB to draw 
differing conclusions regarding the origin of Lp(a), the 
stability of the apo(a)-apoB bond in the Lp(a) particle, and 
the question of whether there is recycling of either Lp(a)-
apo(a) or Lp(a)-apoB. It is important to note that stable 
isotope studies of apo(a) kinetics that use only the enrich-
ment of apo(a), can provide valid data for the FCR of Lp(a) 
in plasma only if model I or model IIa is correct. If there 
is recycling of either apoB or apo(a), as in models IIb 
and III, then there is no single FCR for Lp(a), and individual 
enrichment data for Lp(a)-apo(a) and Lp(a)-apoB must 
be generated and used to calculate the individual FCRs 
of these components of Lp(a). Identification of the “cor-
rect” model will offer critical insights into targets for Lp(a) 
lowering.
Fig. 3. Model IIb: apo(a) and apoB combine to form Lp(a) at the 
same site(s)as in model I, but some Lp(a)-apoB is recycled to the 
Lp(a) assembly site after a circulating Lp(a) is taken up by the liver 
(dashed lines). Lp(a)-apo(a) that is taken up by the liver is all de-
graded. Lp(a) apoB will have a lower enrichment than Lp(a) 
apo(a), with Lp(a) apo(a) having higher FCR and flux than Lp(a) 
apoB.
Fig. 2. Model IIa: apo(a) and apoB combine to form Lp(a) at the 
same site(s) as in model I, but some apo(a) is also secreted from the 
liver and combines with an apoB-lipoprotein in the circulation 
(dashed lines). Lp(a) apoB will have a lower enrichment than Lp(a) 
apo(a), with the same FCR and flux for Lp(a) apo(a) and Lp(a) 
apoB.
Fig. 4. Model III: apo(a) and apoB combine to form Lp(a) at the 
same site(s) as in model I, but some Lp(a)-apo(a) is recycled to the 
Lp(a) assembly site after a circulating Lp(a) is taken up by the liver 
(dashed lines). Lp(a)-apoB that is taken up by the liver is all de-
graded. Lp(a)-apoB has a higher enrichment than Lp(a)-apo(a) 
and also a higher FCR and flux.
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HOW IS Lp(a) CLEARED FROM THE CIRCULATION?
After more than 30 years of work by many investigators 
using cells, animal models, and humans, we continue to 
have great uncertainty about the pathway(s) involved in de-
termining the clearance of Lp(a). This topic was presented 
in a previous review in this series (60), and is an essential 
component of this review as well. Lp(a) levels are increased 
in people with FH, and Kraft et al. (61) reported that for 
Lp(a) with the same allele sizes, the concentration was de-
pendent on the gene dose of LDL receptors. This study 
and others point to an important role for the LDL receptor 
in the clearance of Lp(a) from the circulation. However, 
drugs that clearly increase LDL receptor number, includ-
ing statins, bile acid-binding resins, and ezetimibe, do not 
affect plasma Lp(a) concentrations.
One would expect that kinetic studies, which actually pro-
vide FCRs, would have answered this question. The earliest 
studies, performed by Krempler and colleagues (44, 45), 
used radio-iodinated Lp(a) and found that the FCRs for 
Lp(a) in normal subjects were, as noted earlier in the review, 
about 0.3 pool/day: 30% lower than the FCR they observed 
for LDL apoB-100 (44, 45). In one patient with homozygous 
FH, the FCR of Lp(a) was not different from those in normal 
subjects (45). Despite the differences in Lp(a) and LDL 
apoB-100 metabolism in their first study (44) and the simi-
larities between Lp(a) and LDL FCRs measured in a homozy-
gous FH subject in their second study, the authors concluded 
that their initial kinetic studies did provide support for the 
LDL receptor pathway as the major clearance mechanism for 
Lp(a). Their conclusion hinged strongly on their in vitro 
studies of the binding and uptake of 125LDL and 125Lp(a) by 
fibroblasts from normal and homozygous FH individuals, 
which showed similar effects of the presence or absence of 
LDL receptors between the two lipoproteins. In contrast, 
Maartmann-Moe and Berg (62) reported results indicating 
very different mechanisms for the binding and uptake of 
LDL and Lp(a) in fibroblasts.
A decade later, Knight et al. (46) also using radio-iodinated 
Lp(a), studied normal and FH patients. In the normal group, 
Lp(a) FCRs were similar to those reported by Krempler and 
colleagues (44, 45) and almost 50% slower than the FCRs 
for LDL apoB-100 in the normal subjects. In contrast, there 
were no differences between the FCRs for Lp(a) and LDL 
apoB in the FH group; they were both the same as the 
Lp(a) FCRs in the normal subjects (44, 46). Knight et al. 
(46) also provided evidence suggesting that a remnant of 
Lp(a) with physical characteristics of LDL was generated in 
plasma, offering a solution to the problem of Lp(a) clear-
ance, i.e., there may be more than one pathway involved, 
with the LDL receptor taking an Lp(a) remnant that lacks 
apo(a) out of the circulation while intact Lp(a) is cleared 
by other pathways. In this scenario, both the level of LDL 
receptor activity and the degree of apoB dissociation from 
Lp(a) would be determinants of the apparent Lp(a) FCR. 
As we noted above, however, there is no evidence for a sig-
nificant pool of free apo(a) in the circulation and if dissolu-
tion of the apo(a)-apoB complex in Lp(a) was followed 
by very rapid clearance of free apo(a) leaving behind an 
LDL-apoB, as suggested by Knight et al. (46), the stable 
isotope studies in normal subjects would have FCRs for 
Lp(a) that were similar to those for LDL-apoB.
The results in nonhuman studies have been conflicting 
as well. In 1990, Hofmann et al. (63) reported that Lp(a) 
clearance was accelerated in LDL receptor transgenic 
mice. This group also demonstrated high affinity binding 
of Lp(a) to the LDL receptor. In 1993, Liu et al. (64), using 
LDL receptor-deficient Watanabe rabbits, observed a much 
lower FCR for Lp(a) in Watanabe rabbits compared with 
normal Japanese White rabbits, although there was an even 
greater difference between the FCRs for LDL in the two 
groups of rabbits. Soon after these two reports, Rader et al. (65) 
used radiolabeled tracers to examine the effects of FH on 
the FCRs of LDL apoB-100 and Lp(a). They observed that, 
whereas the removal of LDL apoB was reduced in heterozy-
gous FH patients and even more in homozygous FH pa-
tients compared with normal controls, the FCRs of Lp(a) 
were the same across all three groups (65). In a follow-up 
study, Cain et al. (66) demonstrated similar FCRs for radio-
labeled Lp(a) in wild-type and LDL receptor-deficient 
mice. In the same study, these investigators found that un-
labeled apo(a) was a strong competitor for Lp(a) clearance, 
suggesting that the apo(a) component, rather than apoB-
100, was involved in clearance of Lp(a).
In the era of stable isotope studies, the differences in 
FCRs for Lp(a) and LDL apoB-100 have persisted. Impor-
tantly, despite different methods of isolation of Lp(a) for 
determination of enrichment and differences in sampling 
and feeding protocols during the kinetic studies, the FCRs 
for Lp(a) have been consistently reduced compared with 
those for LDL apoB-100, with a range of FCRs for Lp(a) 
from about 0.10 to 0.35. Of note, a nontracer non-steady state 
study in FH patients undergoing LDL-apheresis reported 
by Parhofer et al. (67) yielded an FCR for Lp(a) of 0.16 pool/
day, similar to results from several tracer kinetic studies.
Our understanding of the role of the LDL receptor in 
Lp(a) catabolism can be informed by studying the effects 
of drugs that affect LDL receptor number. We recently 
reported a 19% reduction in Lp(a) levels in normal sub-
jects receiving the PCSK9 inhibitor, alirocumab, which 
was associated with a trend toward an increase in the FCR 
of Lp(a) of 25% without any change in PR (53). The 
Lp(a) FCR change was small compared with the 80% in-
crease in the LDL apoB FCR. A possible explanation for 
this finding might be that if Lp(a) was being cleared only 
by the LDL receptor, Lp(a) must have a much lower af-
finity for the LDL receptor. On further consideration, 
however, it is clear that the percent increase of ligand 
binding to a receptor should reflect the increase in avail-
able receptors, independent of the affinity of the ligand 
for that receptor. Thus, although Lp(a) may, in general, 
have a lower affinity for the LDL receptor than LDL, an 
increase in the number of LDL receptors should have 
equal relative effects on the FCRs of Lp(a) and LDL. A 
more likely explanation for our result is that Lp(a) is 
cleared by more than one receptor pathway. In this in-
stance, if only the LDL receptors are increased, the in-
crease in the Lp(a) FCR would reflect the proportion of 
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Lp(a) cleared by LDL receptors versus other receptors, 
whereas the increase in FCR for LDL would be directly 
dependent on the increase in LDL receptors. The studies 
by Sharma et al. (22) indicated that a plasminogen recep-
tor is involved in Lp(a) uptake by human hepatoma cells. 
Romagnuolo and colleagues reported that adding supra-
physiological levels of PCSK9 to HepG2 cells reduced 
surface LDL receptors and the internalization of Lp(a) 
(68). A possible role of PCSK9 in the clearance of Lp(a) 
has been suggested by the work of Tavori et al. (69) that 
demonstrated binding of PCSK9 to both Lp(a) and LDL; 
these findings have also been recently reviewed (70).
To add further uncertainty to this issue, we have found 
that mipomersen (apoB antisense) treatment in normal 
subjects lowered Lp(a) by 21% due to an increase in the 
FCR of apo(a) by 27% (unpublished observations). At the 
same time, mipomersen reduced levels of LDL by increasing 
the LDL apoB FCR by 30%, suggesting that the LDL recep-
tor pathway was involved to similar degrees in the changes 
in both Lp(a) and LDL. In contrast, we have also observed 
that reductions of 35% in Lp(a) during treatment of nor-
mal individuals with the CETP inhibitor, anacetrapib, were 
associated with a reduced PR without changes in the FCR 
(unpublished observations). Anacetrapib increased the FCR 
of LDL apoB by 27% in the same study, suggesting that 
there was no link between increased LDL receptors and 
reductions in Lp(a) levels. These results, unfortunately, do 
not add clarity to the question of the role of the LDL receptor 
in Lp(a) clearance from the circulation. The conflicting 
data for the role of the LDL receptor has led investigators 
to examine the binding of Lp(a) to other characterized li-
poprotein receptors. A detailed review of these studies was 
recently published by Hoover-Plow and Huang (25).
Early studies by Kostner and colleagues pointed to the 
kidney as playing a role in Lp(a) clearance (71, 72). These 
investigations identified various fragments of apo(a) not 
bound to apoB that accounted for about 1–3% of the total 
apo(a) in plasma. Importantly, the plasma concentration of 
Lp(a) increases in patients with renal disease, while the uri-
nary excretion of apo(a) fragments decreases, suggesting 
that the kidney is required for the degradation of some 
apo(a). In a small kinetic study by Frischmann et al. (57), 
the FCRs of Lp(a)-apo(a) and Lp(a)-apoB in hemodialysis 
patients were significantly reduced compared with healthy 
subjects; plasma Lp(a) concentrations were nonsignificantly 
increased.
From the authors’ perspective, at present, we do not 
believe that the existing data support any single receptor 
pathway for the clearance of Lp(a) from the circulation. 
The uniformly observed lower FCRs for Lp(a) versus LDL 
do not rule out a role for the LDL receptor, but if the latter 
is involved, then either Lp(a) has a lower affinity for the 
LDL receptor than LDL or the LDL receptor is only one of 
several receptors involved in Lp(a) clearance. The affinity 
of Lp(a) for other receptors, along with the proportion of 
Lp(a) cleared via each of those receptors, will determine 
the background FCR of Lp(a) in an individual, as well 
as the change in FCR when the number of LDL recep-
tors increases. The unraveling of this complex system will 
clearly require further studies. Unfortunately, without a 
physiologic animal model of Lp(a) metabolism, this will be 
very difficult.
CONCLUSIONS
Lp(a) is linked to increased risk for cardiovascular dis-
ease and the development of aortic stenosis. This risk and 
the availability of novel treatments that indirectly and di-
rectly (73–75) lower plasma levels of Lp(a) highlight the 
need to better understand the pathways of assembly, pro-
duction, and clearance of this lipoprotein. Even after 35 
years of excellent work by numerous investigators, addi-
tional studies of plasma Lp(a), Lp(a)-apo(a), and Lp(a)-
apoB metabolism, together with cellular and murine models 
of Lp(a) assembly and uptake, will be needed to fully char-
acterize the regulation of Lp(a) levels in the circulation. 
Future studies of the kinetics of Lp(a) and, more specifically, 
Lp(a)-apo(a) and Lp(a)-apoB must start with purified Lp(a) 
that is free of contamination by other apoB-lipoproteins. 
Studies of the kinetics of Lp(a) isolated in the densities of 
VLDL, IDL, LDL, and HDL will provide information cru-
cial to addressing several of the questions regarding the 
origin and clearance of Lp(a), but this will require efficient 
recovery of Lp(a) from isolated fractions, something that 
has eluded investigators to the present time. Finally, detailed 
characterization of the Lp(a) lipidome and proteome (76) 
would allow examination of the role of Lp(a) composition 
in the regulation of its metabolism.
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